A UCLA-led review analyzes current evidence for AI tools in screening mammography, focusing on their capability to detect interval cancers.
Key Details
- 1UCLA researchers conducted a review of commercially available AI for mammography screening.
- 2The review highlights a need for prospective, real-world data on AI effectiveness and safety.
- 3Interval cancers—cancers developing shortly after a negative screen—are a key focus for AI improvement.
- 4AI retrospectively identified 5% to 78% of technically visible but previously missed cancers, indicating variable sensitivity.
- 5The article calls for more robust data to clarify how these tools should be used in clinical practice.
Why It Matters
Robust, prospective data is crucial before widespread adoption of AI for breast cancer screening. Understanding AI's true sensitivity and potential to reduce missed cancers will directly impact clinical standards in radiology.
Source
Radiology Business
Related News
•AuntMinnie
AI-Driven Whole-Body MRI Biomarkers Aid Myeloma Risk Stratification
AI-powered MRI analysis offers automated risk stratification via body composition in multiple myeloma patients.
•Radiology Business
AI Targets Radiology Residents’ Training Gaps for Personalized Learning
Artificial intelligence can identify gaps in radiology residents' clinical exposure, supporting tailored educational interventions.
•Radiology Business
Vara's AI Gains World's First Approval for Radiologist-Free Mammogram Triage
Vara has secured the world's first regulatory approval for an AI tool that autonomously classifies certain mammograms as normal, bypassing radiologist review.